1191921-01-3

Basic information

• Product Name: (3R,4R,5S)-4-acetylamino-5-acetylamino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester
• Synonyms: (3R,4R,5S)-4-acetylamino-5-acetylamino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester
• CAS NO: 1191921-01-3
• Molecular Weight: 354.447
• Mol File: 1191921-01-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (3R,4R,5S)-4-acetylamino-5-acetylamino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,4R,5S)-4-acetylamino-5-acetylamino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester(1191921-01-3)
• EPA Substance Registry System: (3R,4R,5S)-4-acetylamino-5-acetylamino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester(1191921-01-3)

Safety Data

• Hazardous Substances Data: 1191921-01-3(Hazardous Substances Data)

Usage

Description

(3R,4R,5S)-4-acetylamino-5-acetylamino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester is a cyclohexene carboxylic acid derivative featuring two acetylamino groups at the 4th and 5th positions and an ethylpropoxy group at the 3rd position. (3R,4R,5S)-4-acetylamino-5-acetylamino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester, with its ethyl ester group, suggests potential pharmaceutical or chemical applications and may serve as a prodrug, metabolized into an active drug post-administration.

Uses

Used in Pharmaceutical Applications:
(3R,4R,5S)-4-acetylamino-5-acetylamino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester is used as a potential drug candidate for its possible pharmaceutical applications due to the presence of acetylamino groups, which may offer therapeutic benefits after metabolic conversion.
Used in Chemical Synthesis:
In the chemical industry, (3R,4R,5S)-4-acetylamino-5-acetylamino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester is used as a precursor in chemical synthesis, leveraging its unique structural features to create other valuable compounds or materials.

Upstream product

• 1151665-75-6 (3R,4S,5R)-3-azido-4,5-bis-methanesulfonyloxy-cyclohex-1-enecarboxylic acid ethyl ester 
• 1132659-94-9 (3R,4S,5R)-3,4,5-tris-methanesulfonyloxy-cyclohex-1-enecarboxylic acid ethyl ester 
• 101769-63-5 (3R,4S,5R)-3,4,5-trihydroxycyclohex-1-ene-1-carboxylic acid ethyl ester 
• 138-59-0 shikimic acid 
• 204255-06-1 oseltamivir 
• 1132659-99-4 (3R,4S,5R)-4-acetylamino-3-(1-ethyl-propoxy)-5-methanesulfonyloxy-cyclohex-1-enecarboxylic acid ethyl ester 
• 1151665-77-8 (1S,5R,6S)-ethyl 7-acetyl-5-((methylsulfonyl)oxy)-7-azabicyclo[4.1.0]hept-2-ene-3-carboxylate 
• 108-24-7 acetic anhydride 
• 204255-11-8 oseltamivir phosphate 
• 1151665-76-7 ethyl (1S,5R,6S)-5-methanesulfonyloxy-7-azabicyclo[4.1.0]hept-2-ene-3-carboxylate 
• 64-19-7 acetic acid 
• 196618-13-0 oseltamivir 

Relevant articles and documents

The hydrophobic side chain of oseltamivir influences type A subtype selectivity of neuraminidase inhibitors

Neuraminidase, which plays a critical role in the influenza virus life cycle, is a target for new therapeutic agents. The study of structure–activity relationships revealed that the C-5 position amino group of oseltamivir was pointed to 150-cavity of the neuraminidase in group 1. This cavity is important for selectivity of inhibitors against N1 versus N2 NA. A serial of influenza neuraminidase inhibitors with the oseltamivir scaffold containing lipophilic side chains at the C-5 position have been synthesized and evaluated for their influenza neuraminidase inhibitory activity and selectivity. The results indicated that compound 13o (H5N1 IC50?=?0.1?±?0.04?μm, H3N2 IC50?=?0.26?±?0.18?μm) showed better inhibitory activity and selectivity against the group 1 neuraminidase. This study may provide a clue to design of better group 1 neuraminidase inhibitors.

Synthesis and biological evaluation of NH2-acyl oseltamivir analogues as potent neuraminidase inhibitors

Neuraminidase inhibitors can deter nascent viruses from infecting intact cells by preventing their release from host cells. Herein, a neuraminidase inhibitor 11b absent of basic moieties was discovered in the process of searching for inhibitors targeting 150 cavity. It exhibited potent inhibitions against wild-type neuraminidases from group 1 (H5N1 and H1N1) and group 2 (H7N9) subtypes with IC50 values similar to those of oseltamivir carboxylate. Moreover, 11b showed moderate inhibitions against mutant neuraminidases from H5N1-H274Y and H1N1-H274Y with IC50 values of 2075 nM and 1382 nM, which were inferior to those of oseltamivir carboxylate (6095 nM and 4071 nM). The results were not consistent with the recognized SARs that a basic moiety was an indispensable part of a potent inhibitor.